Targeting VEGF-VEGFR Pathway by Sunitinib in Peripheral Primitive Neuroectodermal Tumor, Paraganglioma and...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Sunitinib malate is a multi-targeted receptor tyrosine kinase inhibitor.
• It is approved for renal cell carcinoma, gastrointestinal stromal tumors, and pancreatic neuroendocrine tumors.
• Rare tumors such as peripheral primitive neuroectodermal tumor (pPNET), paraganglioma (PGL), and epithelioid hemangioendothelioma (EHE) often exhibit pro-angiogenic factor overexpression.

Observation:

• High intratumoral microvessel density is a poor prognostic factor in pPNET, PGL, and EHE.
• Effective treatment options are limited for pre-treated, advanced stages of these rare diseases.
• A preclinical rationale suggests sunitinib's potential efficacy.

Findings:

• This study reports the clinical experience of treating pPNET, PGL, and EHE with sunitinib.
• The findings focus on the outcomes in patients with advanced, pre-treated rare tumor types.
• Sunitinib's activity against relevant tyrosine kinase receptors is highlighted.

Implications:

• Sunitinib may offer a new therapeutic avenue for patients with rare, difficult-to-treat tumors.
• Further research is warranted to establish sunitinib's role in managing pPNET, PGL, and EHE.
• This investigation contributes to understanding kinase inhibitor efficacy in understudied oncological conditions.